ArriVent BioPharma Reports Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
- Nio stock jumps after Goldman Sachs upgrade to buy
- Wall Street posts weekly gains with earnings, inflation data on tap
Oppenheimer Reiterates Outperform Rating on ArriVent BioPharma (AVBP)
March 3, 2025 1:39 PM ESTOppenheimer analyst Jeff Jones reiterated an Outperform rating and $39.00 price target on ArriVent BioPharma (NASDAQ: AVBP).
The analyst comments "On Monday morning, ArriVent BioPharma provided a business update across its pipeline, highlighting progress in 2024, and including year-end financial results. Key updates for AVBP's... More



